NDAT.CN Stock Plunges 22% on April 16, 2026 – nDatalyze Corp. Hits New Lows

NDAT.CN stock collapsed 22.2% on April 16, 2026, closing at just C$0.07 per share. nDatalyze Corp., a Calgary-based healthcare technology company, continues its downward spiral amid persistent operational challenges. The stock has lost 62.5% over the past month alone, signaling deep investor concern. Trading volume remains thin at just 2,250 shares, well below the 27,921-share average. The company’s market cap has shrunk to just C$3.1 million, reflecting severe market skepticism about its business model and financial health.

Why NDAT.CN Stock Is Crashing Today

NDAT.CN stock’s 22% daily plunge reflects broader market concerns about nDatalyze Corp.’s fundamental weakness. The company trades at a price-to-book ratio of 6.58, suggesting the market values it well above its tangible assets. More troubling, NDAT.CN shows negative earnings with an EPS of -C$0.02 and a negative PE ratio of -3.75. The company generated zero revenue in the trailing twelve months, making profitability impossible. Operating cash flow turned negative at -C$0.0035 per share, indicating the business burns cash rather than generates it. These metrics paint a picture of a company struggling to find market traction.

Financial Metrics Show Severe Distress

nDatalyze Corp.’s financial position deteriorated significantly. Return on equity stands at a dismal -34.06%, while return on assets hit -35.34%. The company’s current ratio of 21.6 appears strong on the surface, but this reflects minimal operations rather than financial strength. Free cash flow per share is deeply negative at -C$0.0035, meaning the company cannot fund operations from its business activities. With only C$0.012 in cash per share, nDatalyze Corp. has limited runway. The company’s debt-to-equity ratio of 0.0 shows minimal leverage, but this provides little comfort when operations are unprofitable. Track NDAT.CN on Meyka for real-time updates on this deteriorating situation.

Market Sentiment and Trading Activity

Trading activity in NDAT.CN stock remains extremely thin, with only 2,250 shares changing hands on April 16. This represents just 18.8% of the stock’s average daily volume, indicating minimal investor interest. The stock’s 52-week range spans from C$0.015 to C$0.20, showing extreme volatility and uncertainty. The RSI indicator at 48.3 suggests neither overbought nor oversold conditions, but the CCI at -99.25 signals extreme weakness. Volume liquidation appears minimal given the low trading activity, but the lack of buyers at current prices is telling. Investors are clearly avoiding this stock, with bid-ask spreads likely wide given the illiquidity.

Meyka AI Grade and Analyst Outlook

Meyka AI rates NDAT.CN with a grade of C, reflecting significant concerns about the company’s viability. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The rating recommendation is Sell, with a score of just 2 out of 10. Individual component scores are alarming: ROE receives a Strong Sell rating, ROA gets Strong Sell, and the debt-to-equity ratio earns Strong Sell. Only the price-to-book ratio receives a Buy rating, suggesting the stock may be undervalued on a book value basis. These grades are not guaranteed and we are not financial advisors. The overall picture suggests extreme caution for potential investors.

Business Model and Operational Challenges

nDatalyze Corp. operates in the healthcare technology sector, developing machine-learning based mental health applications and database licensing solutions. The company also manufactures CO2 extraction and alcohol-based equipment for medical cannabis growers. With only 10 full-time employees and headquarters in Calgary, Alberta, the company operates at minimal scale. The lack of revenue generation indicates the business has not achieved commercial traction. The company was formerly known as MedXtractor Corp. before rebranding in October 2021. Despite pivoting to healthcare technology, nDatalyze Corp. has failed to generate meaningful revenue or profitability, suggesting fundamental challenges with market demand or execution.

Price Forecast and Future Outlook

Meyka AI’s forecast model projects NDAT.CN at C$0.09 monthly and C$0.07 quarterly, suggesting modest recovery from current levels. The monthly forecast implies 28.6% upside from the current C$0.07 price, while the quarterly forecast suggests the stock may hold current levels. However, forecasts are model-based projections and not guarantees. The company’s year-to-date performance shows a 400% gain, but this reflects recovery from extremely depressed levels rather than fundamental improvement. The 52-week high of C$0.20 remains far above current trading levels, indicating significant downside risk if the company’s situation deteriorates further. Investors should demand clear evidence of revenue generation before considering this stock.

Final Thoughts

NDAT.CN stock’s 22% crash on April 16, 2026 reflects the harsh reality of a company struggling to survive. nDatalyze Corp. faces multiple headwinds: zero revenue, negative cash flow, unprofitable operations, and minimal market interest. The C-grade rating from Meyka AI and Sell recommendation underscore the risks. With a market cap of just C$3.1 million and only 10 employees, the company operates at minimal scale. The stock’s extreme volatility and thin trading volume make it highly speculative. While the price-to-book ratio suggests potential value, this means little without revenue or a clear path to profitability. Investors should carefully evaluate whether nDatalyze Corp. can execute its healthcare technology strategy before committing capital. The company must demonstrate revenue generation and a clear business model to justify any investment.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.